ARAF and lung carcinoma: Given that lung cancer is the most frequent type of cancer worldwide, with ~2.5 million new cases in 2022 [1], an estimated 750 lung cancer patients per year may harbor the ARAF p.S214C mutation and could potentially benefit from sorafenib treatment.